Low Recurrence After Risk-Reducing Surgery for BRCA Carriers Low Recurrence After Risk-Reducing Surgery for BRCA Carriers

Dr Maurie Markman discusses the results of an RRSO surgery study showing a 1% incidence rate in long-term follow-up of subsequent peritoneal cancer.Medscape Oncology
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Authors: Han S, Dwivedi P, Mangrio FA, Dwivedi M, Khatik R, Cohn DE, Si T, Xu RX Abstract The current clinical paradigm for ovarian cancer treatment has a poor prognosis, partially due to the efficacy and toxicity concerns associated with the available chemotherapeutic formulations. To overcome these limitations, we have designed core-shell-structured paclitaxel (PTX) laden solid lipid microparticles (PTX-SLMPs) for intraperitoneal treatment of ovarian cancer. A single-step coaxial electro hydrodynamic atomization (CEHDA) process has been explored to synthesize core-shell structure of PTX-SLMPs with the particle si...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Publication date: Available online 20 March 2019Source: European Journal of Surgical OncologyAuthor(s): Matthieu Siebert, Mohammad Alyami, Frederic Mercier, Colin Gallice, Laurent Villeneuve, Nathalie Laplace, Guillaume Passot, Naoual Bakrin, Olivier Glehen, Vahan KepenekianAbstractIntroductionPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising technic for unresectable peritoneal metastasis (PM). Targeted therapies such as bevacizumab have demonstrated their efficacy in advanced colorectal and ovarian cancer. We aimed to evaluate the feasibility and safety of this bidimensional therapeutic association.M...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Approximately 20 –30% of patients with pT4 colon cancer develop metachronous peritoneal metastases (PM). Due to restricted accuracy of imaging modalities and absence of early symptoms, PM are often detected at ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
ConclusionsFollowing NACT, the rate of optimal IDS might be improved for patients without multisite bowel involvement. For those with bowel involvement, management strategy made by well-experienced surgeons might be a key factor for the outcome of IDS.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
ConclusionDW-MRI is accurate in predicting the S-PCI and can be helpful to predict whether a complete resection in ovarian cancer patients is feasible.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Publication date: Available online 15 March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): V. Lavoue, C. Huchon, C. Akladios, P. Alfonsi, N. Bakrin, M. Ballester, S. Bendifallah, P.A. Bolze, F. Bonnet, C. Bourgin, N. Chabbert-Buffet, P. Collinet, B. Courbiere, T. De la motte rouge, M. Devouassoux-Shisheboran, C. Falandry, G. Ferron, L. Fournier, L. Gladieff, F. GolfierAbstractAn MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, ...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
CONCLUSIONS: Following NACT, the rate of optimal IDS might be improved for patients without multisite bowel involvement. For those with bowel involvement, management strategy made by well-experienced surgeons might be a key factor for the outcome of IDS. PMID: 30885671 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
ConclusionsThe mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T  >  G and c.5266dupCBRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research
AbstractObjectivesThe peritoneal cancer index (PCI) is widely used for assessing pseudomyxoma peritonei (PMP) in surgery. The aim of this study was to evaluate the utility of a modified PCI using 18F-fluorodeoxyglucose (18F-FDG)-PET/CT (PET-PCI) for predicting pathologic grade and progression-free survival (PFS) in patients with PMP.MethodsThirty-five patients who underwent 18F-FDG-PET/CT before cytoreductive surgery and/or hyperthermic intraperitoneal chemotherapy were enrolled. PET-PCI was determined by summing up the visually scored 18F-FDG uptake of PMP lesions in 13 specific abdominal-pelvic regions. Uptake score was ...
Source: European Radiology - Category: Radiology Source Type: research
ConclusionsGHG –CDDP is a promising treatment option for peritoneal metastases through the complete sustained-release of CDDP with less systemic toxicity.
Source: Surgery Today - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Peritoneal Cancer | Study | Surgery